Multiple Myeloma
📧 Sign up to get email alerts when something new happens for Multiple Myeloma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2024-08-16Clinical Trial Update: The TOTOM Trial: Tai Chi to Optimize Transplant Outcomes for Multiple Myeloma [NA]
Clinical trial update for the TOTOM Trial evaluating Tai Chi to optimize transplant outcomes in multiple myeloma. The study status is comple…
-
CLINICAL_TRIALS trial_result · 2024-08-13Clinical Trial Update: Finistere Myeloma Observatory (OMYFIN)
The Finistere Myeloma Observatory (OMYFIN) trial for multiple myeloma has completed enrollment. The sponsor is University Hospital, Brest.
-
CLINICAL_TRIALS research · 2024-08-09Clinical Trial Update: Dysregulation of Glutamine Activity in the Pathogenesis of Multiple Myeloma [NA]
A completed clinical trial update examining whether dysregulated glutamine metabolism contributes to the pathogenesis of multiple myeloma. T…
-
CLINICAL_TRIALS other · 2024-08-09Clinical Trial Update: Elranatamab Expanded Access Protocol in Adults With Relapsed/Refractory Multiple Myeloma
The expanded access program for Elranatamab in adults with relapsed/refractory multiple myeloma has been updated and is no longer available.
-
CLINICAL_TRIALS research · 2024-08-07Clinical Trial Update: DAratumumab and REvlimid REfractory MM
A clinical trial evaluating daratumumab in combination with lenalidomide (Revlimid) for relapsed/refractory multiple myeloma is currently re…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2024-08-02Clinical Trial Update: Effect of AT7519M Alone and AT7519M Plus Bortezomib in Patients With Previously Treated Multiple Myeloma [Phase 1, Phase 2]
Clinical trial update for AT7519M alone and in combination with bortezomib in previously treated multiple myeloma (Phase 1/Phase 2; complete…
-
CLINICAL_TRIALS research · 2024-08-02Clinical Trial Update: A Study to Evaluate the Safety, PK/PD of (OriCAR-017) in Subjects With RR/MM - RIGEL Study [Phase 1]
Phase 1 study evaluating the safety and PK/PD of OriCAR-017 in subjects with relapsed/refractory multiple myeloma is currently recruiting.
-
CLINICAL_TRIALS trial_result · 2024-08-01Clinical Trial Update: Testing the Addition of Ixazomib/Placebo to Lenalidomide in Patients With Evidence of Residual Multiple Myeloma, OPTIMUM Trial [Phase 3]
A Phase 3 trial (OPTIMUM) tested adding ixazomib or placebo to lenalidomide in patients with residual multiple myeloma. The study has comple…
-
CLINICAL_TRIALS trial_result · 2024-08-01Clinical Trial Update: Evaluation of IGM-2644 in Adults With Relapsed and/or Refractory Multiple Myeloma [Phase 1]
The Phase 1 study evaluating IGM-2644 in adults with relapsed and/or refractory multiple myeloma was terminated.
-
CLINICAL_TRIALS trial_result · 2024-08-01Clinical Trial Update: Ixazomib, Lenalidomide, and Combination for Maintenance in NDMM Patients [Phase 4]
Phase 4 maintenance trial in newly diagnosed multiple myeloma evaluating ixazomib, lenalidomide, and the combination.
-
CLINICAL_TRIALS trial_result · 2024-08-01Clinical Trial Update: The clonoSEQ® Watch Registry
Clinical trial update for the clonoSEQ Watch Registry sponsored by Adaptive Biotechnologies; the study status is terminated.
-
EMA approval · 2024-07-31EMA Authorised: Mozobil (Plerixafor) — Sanofi B.V.
The EMA authorised Mozobil (plerixafor) from Sanofi B.V. for multiple myeloma and lymphoma indications, including use in hematopoietic stem …
-
CLINICAL_TRIALS research · 2024-07-31Clinical Trial Update: Early Integration of Palliative and Supportive Care in Cellular Therapy [NA]
This clinical trial is evaluating early integration of palliative and supportive care in cellular therapy for hematologic cancers and is cur…
-
CLINICAL_TRIALS research · 2024-07-31Clinical Trial Update: Cytogenetic Studies in Acute Leukemia and Multiple Myeloma
Update on cytogenetic studies in acute leukemia and multiple myeloma; the trial is currently active but not recruiting.
-
FDA approval · 2024-07-30FDA Approved: DARZALEX FASPRO — Supplemental Application (Janssen Biotech, Inc.)
The FDA approved a supplemental application for DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) from Janssen Biotech, Inc. The notice i…
-
CLINICAL_TRIALS trial_result · 2024-07-30Clinical Trial Update: A Study to Learn About the Study Medicine (Elranatamab) in Participants With Multiple Myeloma That Has Come Back After Responding to Treatment or Has Not Responded to Treatment [Phase 2]
Phase 2 trial update evaluating elranatamab in relapsed or refractory multiple myeloma; results are posted.
-
CLINICAL_TRIALS trial_result · 2024-07-26Clinical Trial Update: Phase I: Melphalan, Bendamustine and Carfilzomib for Autologous Transplant in Multiple Myeloma [Phase 1]
Phase I study evaluating a melphalan, bendamustine, and carfilzomib regimen for autologous stem cell transplantation in multiple myeloma; th…
-
CLINICAL_TRIALS trial_result · 2024-07-26Clinical Trial Update: A Study of CC-98633, BCMA-targeted Chimeric Antigen Receptor (CAR) T Cells, in Participants With Relapsed and/or Refractory Multiple Myeloma [Phase 1]
A Phase 1 study evaluating CC-98633, a BCMA-targeted CAR T-cell therapy, in relapsed and/or refractory multiple myeloma has completed.
-
CLINICAL_TRIALS research · 2024-07-25Clinical Trial Update: BCMA CAR-T Cell Therapy in High-risk NDMM Patients With Positive MRD After First-line ASCT [Phase 2]
A Phase 2 clinical trial evaluating BCMA CAR-T cell therapy in high-risk newly diagnosed multiple myeloma patients who remain MRD-positive a…
-
CLINICAL_TRIALS trial_result · 2024-07-25Clinical Trial Update: Dose-escalation Study of Oral Administration of S 55746 in Patients With Chronic Lymphocytic Leukaemia and B-Cell Non-Hodgkin Lymphoma [Phase 1]
Phase I dose-escalation study of oral S-55746 in patients with chronic lymphocytic leukemia and B-cell non-Hodgkin lymphoma completed.
-
CLINICAL_TRIALS trial_result · 2024-07-25Clinical Trial Update: Study of Tinostamustine, First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies [Phase 1]
Tinostamustine, a first-in-class alkylating HDAC inhibitor fusion molecule, completed its Phase 1 study in relapsed/refractory hematologic m…
-
CLINICAL_TRIALS research · 2024-07-25Clinical Trial Update: Comparison Study of EAP and CG Regimens for Mobilizing Hematopoietic Stem Cells in Multiple Myeloma Patients [Phase 3]
Phase 3 clinical trial comparing EAP and CG regimens for mobilizing hematopoietic stem cells in patients with multiple myeloma; currently re…
-
CLINICAL_TRIALS trial_result · 2024-07-24Clinical Trial Update: A Study of Real-World Use of Ixazomib Citrate in People With Multiple Myeloma (MM)
A real-world study evaluating ixazomib citrate in people with multiple myeloma has completed. The sponsor is Takeda.
-
CLINICAL_TRIALS research · 2024-07-24Clinical Trial Update: Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma [Phase 1, Phase 2]
A Phase 1/2 clinical trial to assess the safety of HDP-101 in patients with relapsed or refractory multiple myeloma; the study is currently …
-
CLINICAL_TRIALS research · 2024-07-23Clinical Trial Update: Integrative Therapies in Multiple Myeloma [NA]
A clinical trial update indicates a study evaluating integrative therapies for multiple myeloma is currently recruiting.